

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number
WO 2004/009583 A2

(51) International Patent Classification⁷: **C07D 401/00**

(21) International Application Number:
PCT/US2003/022419

(22) International Filing Date: 15 July 2003 (15.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/397,459 19 July 2002 (19.07.2002) US

(71) Applicants and

(72) Inventors: **GARST, Michael, E.** [US/US]; 2627 Raqueta Drive, Newport Beach, CA 92660 (US). **SACHS, George** [US/US]; 17986 Boris Drive, Encino, CA 91316 (US). **SHIN, Jai, Moo** [US/US]; 18833 Nau Avenue, Northridge, CA 91326 (US).

(74) Agent: **SZEKERES, Gabor, L.**; 8141 East Kaiser Boulevard, Suite 112, Anaheim Hills, CA 92808 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PRODRUGS OF PROTON PUMP INHIBITORS



(57) Abstract: Prodrugs of proton pump inhibitors of Formulas 1 through 4, (I-IV), where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability.

WO 2004/009583 A2